Simulect

Active Ingredient(s): Basiliximab
FDA Approved: * May 12, 1998
Pharm Company: * NOVARTIS
Category: Immunosuppressive

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Simulect Overview

Basiliximab (trade name Simulect) is a chimeric mouse-human monoclonal antibody to the α chain (CD25) of the IL-2 receptor of T cells. It is used to prevent rejection in organ transplantation, especially in kidney transplants. Contents 1 Uses 2 Mechanism of action 3 Chemistry 4 History 5 See also 6 References and notes Uses Basiliximab is an immunosuppressant agent used to prevent immediate transplant rejection in people who are receiving kidney transplants, in combination with o...

Read more Simulect Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Basiliximab

Recent Simulect Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Simulect: (2 results)

Sorted by National Drug Code

• 0078-0331 Simulect 20 mg/5ml Intravenous Injection, Powder, for Solution by Novartis Pharmaceuticals Corporation
• 0078-0393 Simulect 10 mg/2.5ml Intravenous Injection, Powder, for Solution by Novartis Pharmaceuticals Corporation

Other drugs which contain Basiliximab or a similar ingredient: (1 result)

• BASILIXIMAB